FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids

The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as government advisers on Oct. 26 endorsed kid-size doses of Pfizer's shots for 5- to 11-year-olds.

A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine's benefits in preventing COVID-19 in that age group outweigh any potential risks. That includes questions about a heart-related side effect that's been very rare in teens and young adults despite their use of a much higher vaccine dose.

While children are far less likely than older people to get severe COVID-19, ultimately many panelists decided it's important to give parents the choice to protect their youngsters, especially those at high risk of illness or who live in places where other precautions, like masks in schools, aren't being used.

"This is an age group that deserves and should have the same opportunity to be vaccinated as every other age," said panel member Dr. Amanda Cohn of the Centers for Disease Control and Prevention.

The FDA isn't bound by the panel's recommendation and is expected to make its own decision within days. If the FDA concurs, there's still another step: Next week, the CDC will have to decide whether to recommend the shots and which youngsters should get them.

Full-strength shots made by Pfizer and its partner BioNTech already are recommended for everyone 12 and older but pediatricians and many parents are clamoring for protection for younger children. The extra-contagious delta variant has caused an alarming rise in pediatric infections - and families are frustrated with school quarantines and having to say no to sleepovers and other rites of childhood to keep the virus at bay.

In the 5- to 11-year-old...